Latest Personalized medicine Stories
New offer improves pharmaceutical companies' ability to better evaluate patients eligible for personalized medicine. New York, NY (PRWEB) May 23, 2013 Kantar Health, a leading global healthcare advisory firm, today announced the availability of CancerMPact® Biomarker Analysis, a global offer that examines biomarker segmentation in the current and evolving oncology landscape. The analysis is based on a thorough review of literature and recently published data covering the...
LAUSANNE, Switzerland and DRESDEN, Germany, May 23, 2013 /PRNewswire/ -- Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced...
Exciting new precision medicine tool for diagnosing and guiding treatment of patients with NEPC Prostate Cancer BUFFALO, N.Y., May 22, 2013 /PRNewswire/ -- Empire Genomics announced today it has acquired an exclusive license for a patent pending novel genomic biomarker from Cornell University for use in developing a molecular diagnostic test that could help in diagnosing and determining treatment for patients with neuroendocrine (NEPC) prostate cancer. Neuroendocrine prostate...
PHILADELPHIA and REHOVOT, Israel, May 22, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, will deliver a corporate update at the Jefferies 2013 Healthcare Conference taking place from June 3-6, 2013 in New York City. Mr. Berlin's presentation will take place on Tuesday, June 4(th) at 2:00 p.m. Eastern time....
Preferred Provider Organization network has more than 6.5 million covered lives PHILADELPHIA and REHOVOT, Israel, May 20, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has executed a credentialing agreement with Prime Health Services, Inc. (Prime Health), a managed care company that offers a full spectrum of services, including a Preferred Provider...
WASHINGTON, May 17, 2013 /PRNewswire-USNewswire/ -- Personalized medicine and targeted therapies hold great potential to improve patient care and health care efficiency. At the Ninth Annual State of Personalized Medicine Luncheon hosted by the Personalized Medicine Coalition (PC), Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research at the Food and Drug Administration (FDA), will discuss how the FDA is dealing with the expanding field of personalized medicine,...
Genetic Testing is Surprisingly Easy and Affordable According to Author of New Gene Patch Medicine Book SAN FRANCISCO, May 17, 2013 /PRNewswire/ -- When Angelina Jolie told the world about her double mastectomy, she expressed a wish for all women with a family history of breast cancer: "It is my hope that they, too, will be able to get gene tested, and that if they have a high risk they, too, will know that they have strong options." You may think that such a test is something only...
TUCSON, Ariz. and BOSTON, May 15, 2013 /PRNewswire/ -- DxInsights, a nonprofit, independent organization dedicated to educating industry, academicians, healthcare community and payers on the power of diagnostics, has announced the appointment of Ethan K. Knowlden as Executive Director. Mr. Knowlden will work directly with DxInsights' Board and Steering Committee and will be responsible for the operations and activities of the association on a day-to-day basis, in addition to...
Collaboration connects gene expression data and physiological mechanistic model simulations that should illuminate best treatment for selected patients. San Mateo, CA (PRWEB) May 14, 2013 Entelos Holding Corp. (“Entelos” or “the Company”), a premier provider of physiological system modeling and services, and Seattle-based Institute for System Biology (ISB), the nonprofit pioneers of the systems approach to study the molecular causes of diseases, today announced the successful...
New personalized medicine initiative enables doctors to tailor drug therapies to individual patients based on genetic profile BALTIMORE, May 14, 2013 /PRNewswire-USNewswire/ -- Patients with coronary artery disease who undergo treatment at the University of Maryland Medical Center now can receive long-term therapy based on information found in their genes. As part of a new personalized medicine initiative, the medical center is offering genetic testing to help doctors determine which...
